Format

Send to

Choose Destination
Gut Liver. 2018 May 15;12(3):324-330. doi: 10.5009/gnl17298.

Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety.

Lee HW1,2,3, Oh SR1, Kim DY1, Jeong Y1,4, Kim S1,2,3, Kim BK1,2,3, Kim SU1,2,3, Kim DY1,2,3, Ahn SH1,2,3, Han KH1,2,3, Park JY1,2,3.

Author information

1
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
2
Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.
3
Yonsei Liver Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
4
Brain Korea 21 PLUS Project for Medical Science College of Medicine, Seoul, Korea.

Abstract

Background/Aims:

The treatment with daclatasvir plus asunaprevir (DCV+ASV) is associated with potent antiviral effects in patients with genotype 1b hepatitis C virus (HCV) infection. We investigated the real-world efficacy, changes in liver stiffness and noninvasive fibrosis markers, and the safety of DCV+ASV treatment in Korean patients.

Methods:

In total, 363 patients with chronic hepatitis C were treated with DCV+ASV between August 2015 and January 2017. Finally, we analyzed the data of 270 patients who were monitored for at least 12 weeks after the end of treatment.

Results:

The mean age was 60.7 years, and females predominated (60.4%). Most patients (64.8%) were treatment-naïve, and 56 patients (20.7%) had cirrhosis. Two hundred fifty-seven (95.2%) and 251 (93.0%) patients achieved end-of-treatment responses and sustained virological responses at 12 weeks posttreatment (SVR12), respectively. The SVR12 rates were higher in patients who were <65 years of age, males, without cirrhosis and had lower HCV RNA levels. All LS values and fibrosis-4 and aspartate aminotransferase-to-platelet ratio index values declined from baseline to the time of assessment of SVR12.

Conclusions:

The DCV+ASV therapy resulted in a high SVR12 and improved liver fibrosis; the treatment was well tolerated in patients with genotype 1b HCV infections.

KEYWORDS:

Asunaprevir; Daclatasvir; Fibrosis; Genotype 1b; Hepatitis C

PMID:
29409309
PMCID:
PMC5945264
DOI:
10.5009/gnl17298
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Inforang Icon for PubMed Central
Loading ...
Support Center